FUCHS HENRY J
Known title: President, Worldwide R&DCIK: 0001197355
Associated companies
Transaction History
| BMRN | ▼ Sell | Tax Withholding | 12,098 | $1.0M | 9/13/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 300 | $21K | 4/30/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 18,240 | $0 | 3/15/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 33,485 | $2.8M | 3/15/2024 | View on chart |
| BMRN | ▼ Sell | Open Market | 35,341 | $3.0M | 3/5/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 30,640 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 13,326 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 9,238 | $0 | 2/27/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 17,750 | $0 | 12/1/2023 | View on chart |
| BMRN | ▼ Sell | Open Market | 12,000 | $1.1M | 8/10/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 317 | $21K | 4/28/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 36,000 | $3.4M | 3/16/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 4,799 | $421K | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 16,840 | $0 | 3/15/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 36,440 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 18,220 | $0 | 2/28/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 13,392 | $0 | 2/28/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 2,259 | $182K | 3/16/2022 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 12,101 | $947K | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 38,790 | $0 | 3/15/2022 | View on chart |
| BMRN | ▲ Buy | Grant | 12,840 | $0 | 3/8/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership
BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.